ALSO NOTED: Bayer drug moves up to first-line leukemia treatment; St. Jude Medical adding 1,200 jobs in Puerto Rico

> Bayer got the FDA's blessing to market its Campath leukemia drug as a first-line treatment against the disease; previously, Campath was only approved for use when other therapies had failed. Made by Genzyme, the drug is marketed by Bayer under license in the U.S. Release

> Device maker St. Jude Medical says it will add 1,200 new jobs in Arecibo, Puerto Rico as it ramps up production at a newly purchased plant there. Report

> Cardinal Health and Alliance Boots are joining forces to launch the generic brand Almus in the U.S. Report

> Indian drug maker Ranbaxy Laboratories says it will appeal a Canadian court's decision to block its launch of a generic form of Lipitor, Pfizer's blockbuster cholesterol drug. Report

> Novo Nordisk got E.U. approval to use its NovoRapid insulin product in the elderly. Report

> According to new trial data, Merck's Gardasil vaccine against the virus that causes cervical cancer also cross-protects against 10 strains not directly targeted by the shot--making it useful in developing countries where those 10 strains are most prevalent. Report

> Celera Group agreed to buy Atria Genetics, a maker of bone marrow testing products, for $33 million. Report

And Finally... Forget diet and exercise--there's a shot that'll zap fat away. Trouble is, it's not FDA-approved, it's not standardized and it could be dangerous. Report